DWA
BMY.RT

Dougherty Wealth Advisers’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Dougherty Wealth Advisers’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,070
Closed -$1K – 151
2020
Q4 		$1K Hold
1,070
– – ﹤0.01% 144
2020
Q3 		$2K Hold
1,070
– – 0.01% 146
2020
Q2 		$4K Buy
+1,070
New +$3.86K 0.01% 152

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Dougherty Wealth Advisers's BMY.RT Position: Q1 2021 in Review

Dougherty Wealth Advisers sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 1,070 shares — an estimated $1K sold.

Dougherty Wealth Advisers first reported a position in BMY.RT in Q2 2020 and held it in 3 quarters. The position peaked at $4K in Q2 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Dougherty Wealth Advisers reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Dougherty Wealth Advisers sold 1,070 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $1K.
  • Dougherty Wealth Advisers first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q2 2020 and held it in 3 quarters.
  • Dougherty Wealth Advisers's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $4K in Q2 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Dougherty Wealth Advisers's 13F filing for Q1 2021, filed 6 May 2021.